Global HDL Cholesterol Kits Market - 2024-2031

Global HDL Cholesterol Kits Market - 2024-2031

The global HDL cholesterol kits market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Plasma lipoproteins include many primary types, one of which is high-density lipoproteins (HDL). They vary in size and lipid and apolipoprotein content and are made up of many heterogeneous particles, including cholesterol. HDL is responsible for transferring cholesterol from peripheral cells to the liver, where it is transformed into bile acids and eliminated through the intestines.

Precise evaluation of HDL-C is essential for determining a patient's risk of coronary heart disease. When direct measurement is used instead of precipitation techniques, accuracy and repeatability are increased. Typically, HDL is ordered in conjunction with additional tests, such as those for cholesterol or lipid profiles that include triglycerides and LDL. HDL and total cholesterol together are a highly helpful screening tool for heart disease risk.

Market Dynamics: Drivers

Rising prevalence of cardiovascular conditions

As the global population is rising especially the old-age demographic, the incidence of cardiovascular conditions such as stroke, atherosclerosis, coronary artery disease, and heart attack are also expected to rise, creating a huge demand for medical intervention. As per the United Nations statistics, by 2030, the global population is predicted to reach 8.5 billion and in 2050 to 9.7 billion. As per the World Health Organization (WHO) estimates, the old-age population above 60 years would be nearly 1.4 billion in 2030 and 2.1 billion in 2050.

The major culprit behind majority of the cardiovascular conditions is low-density lipoprotein (LDL), very low-density lipoproteins (VLDL), triglycerides, and cholesterol. Accumulation of these will lead to blockage of blood circulation to various parts of the body that results in serious morbid conditions. The high-density lipoprotein (HDL), also known as good cholesterol, is known to reduce the levels of bad cholesterol, especially LDL. This HDL helps to break down the LDL that forms thrombus in the blood vessels and transport it back to the liver, where the LDL is sequestered and eliminated from the body or stored in the form of lipid cells.

Testing for HDL-C is done to evaluate the patient’s cardiovascular health, including their risk of heart disease. Good cholesterol, or HDL-C, is linked to a decreased risk of coronary heart disease events. The ratio of HDL-C to non-HDL cholesterol may be readily computed by the physician by measuring both total cholesterol and HDL-C in the same blood sample, which is vital for evaluating the patient’s cardiovascular health.

The aging population demographic, sedentary lifestyle, and change in eating habits in the modern world are expected to increase the risk of cardiovascular disease incidence.

For instance, American Heart Association, Inc. states that around 18 million deaths globally are attributed to cardiovascular disease (CVD), with significant differences between high- and low-income countries (HICs) and LMICs. LMICs bear a disproportionate amount of the global burden of cardiovascular diseases (CVDs), accounting for 80% of all cardiovascular deaths globally.

In addition, as per the National Heart Foundation of Australia, one in six Australians is living with a cardiovascular disease accounting for nearly 4.5 million cases, which represent 18% of the total Australian population. In addition, more than 1500 hospital admissions and 24% of all deaths in Australia are attributed to CVD.

As this trend is expected to rise, the demand for preventative health measures is expected to rise that include timely heart health monitoring, is expected to create a huge demand for HDL cholesterol testing kits in the forecast period.

Restraints

The high cost of HDL cholesterol kits is one of the restraining factors that may hinder market growth. This can be an economic burden to small-scale health centers and clinics with low operational budgets. In addition, the lack of awareness among patients especially those living in rural areas regarding the importance of regular cholesterol checkups is another factor that may restrain the market growth.

For more details on this report - Request for Sample

Segment Analysis

The global HDL cholesterol kits market is segmented based on product type, modality, end-users, and region.

The colorimetry based kits in the type segment accounted for approximately 56.4% of the global HDL cholesterol kits market share

HDL cholesterol is routinely evaluated together with total cholesterol, LDL cholesterol, and triglycerides to track each patient's unique risk of developing cardiovascular disease. The most popular method for measuring HDL cholesterol is enzymatic colorimetric techniques, the gold standard for lipid analysis of this kind. Since the development of color is the endpoint in this process, the intensity, and other parameters can be estimated by employing ultraviolet-visible spectroscopy at 500 nm. This is a widely accepted method due to its simplicity, cost-effectiveness, sensitivity, and specificity. Moreover, many HDL detection kits manufactured by prominent players utilize the colorimetric method.

Geographical Analysis

North America is expected to dominate the market with a 43.2% share in the global HDL cholesterol kits market

North America is expected to dominate the market due to its well-advanced healthcare infrastructure, state-of-the-art diagnostic centers, clinical laboratories, etc. Moreover, the the major high-income countries in the region the U.S. and Canada are well-known for their investments in the healthcare industry

For instance, Laboratory Corporation of America Holdings has nearly 2,000 centers spanning across the U.S. providing several diagnostic testing services including the cholesterol panel. Quest Diagnostics, another prominent diagnostic service provider has over 2,000 of its patient service centers and nearly 7,400 patient access points in the U.S.

This well-established network of clinical laboratories provides testing services all across the nation making the service easily accessible by all the population.

Moreover, the region is known for its high prevalence of cardiovascular-related events. As per the American Heart Association’s heart disease and stroke statistics 2024 update, nearly 222.4 per 100,000 patients age-adjusted death rate attributable to CVD, and nearly 25.5% of the U.S. adult population have their LDL-cholesterol greater than 130mg/dL. Low-density lipoprotein (LDL) is the major culprit in the majority of cardiovascular conditions such as ischemia, atherosclerosis, and stroke. Moreover, nearly 9.7 million people in the U.S. have undiagnosed diabetes, 29.3 million people have been diagnosed with diabetes and 115.9 million people are at risk of pre-diabetes.

Considering the high prevalence of cardiovascular indications, and the well-established healthcare systems combined with top-tier clinical laboratories providing HDL testing services the demand and the sales volume of HDL cholesterol kits is far higher in the North American region. In addition, most market leaders have established a stronghold market position in the region, making the kits easily available to healthcare facilities. All these factors are expected to be contributing to the region’s dominance in the global market for HDL cholesterol kits.

Covid-19 Analysis

The Covid-19 pandemic had a significant impact on the market of HDL cholesterol kits. During the pandemic, the global supply chain has been disrupted due to imposed restrictions on movement and lockdowns. The restriction in movement has reduced the hospital and clinical laboratory visits by the patients, which is anticipated to have resulted in decreased HDL cholesterol testing volumes. Moreover, the clinical labs and hospitals were majorly focused on providing testing services to the Covid-infected patients which is anticipated to have resulted in decreased testing volume.

For instance, a study conducted in the Mass General Brigham (MGB) which is a large integrated healthcare system serving Massachusetts and its neighboring states, has found a 39.2% decline in weekly cholesterol tests from 6,361 in 2019 to 3,867 in 2020, with the greatest reductions occurring during the first wave of the pandemic accounting for 92% reduction in the testing volume.

Market Segmentation

By Type
• Colorimetry Based Kits
• Fluorometry Based Kits
• Precipitation Based Kits
• Others

By Sample Type
• Serum
• Plasma
• Urine
• Others

By End-Users
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major players in the HDL cholesterol kits market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Merck KGaA, Randox Laboratories Ltd., SEKISUI Diagnostics, Abcam Limited., Diazyme Laboratories, Inc., Cell Biolabs, Inc. and DiaSys Diagnostic Systems GmbH among others.

Why Purchase the Report??
• To visualize the global HDL cholesterol kits market segmentation based on type, sample type, end-users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of HDL cholesterol kits market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global HDL cholesterol kits market report would provide approximately 62 tables, 55 figures, and 187 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies